What Lies Ahead for 2016: The DIA's Annual Report

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.

Hyfe’s CEO discusses the importance of DTx and how it can change the way certain conditions are treated.

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.